- Home
- BRNS vs BCTX Comparison
BRNS vs BCTX Comparison
Compare BRNS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- BCTX
- Stock Information
- Founded
- BRNS 2016
- BCTX 2014
- Country
- BRNS United Kingdom
- BCTX Canada
- Employees
- BRNS N/A
- BCTX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- BCTX Health Care
- Exchange
- BRNS Nasdaq
- BCTX Nasdaq
- Market Cap
- BRNS 41.0M
- BCTX 34.6M
- IPO Year
- BRNS 2021
- BCTX N/A
- Fundamental
- Price
- BRNS $1.04
- BCTX $0.38
- Analyst Decision
- BRNS Strong Buy
- BCTX Strong Buy
- Analyst Count
- BRNS 2
- BCTX 1
- Target Price
- BRNS $3.00
- BCTX $15.00
- AVG Volume (30 Days)
- BRNS 46.0K
- BCTX 1.0M
- Earning Date
- BRNS 11-06-2024
- BCTX 12-16-2024
- Dividend Yield
- BRNS N/A
- BCTX N/A
- EPS Growth
- BRNS N/A
- BCTX N/A
- EPS
- BRNS N/A
- BCTX N/A
- Revenue
- BRNS $14,969,000.00
- BCTX N/A
- Revenue This Year
- BRNS $1,805.74
- BCTX N/A
- Revenue Next Year
- BRNS N/A
- BCTX N/A
- P/E Ratio
- BRNS N/A
- BCTX N/A
- Revenue Growth
- BRNS 106.21
- BCTX N/A
- 52 Week Low
- BRNS $0.80
- BCTX $0.37
- 52 Week High
- BRNS $4.16
- BCTX $4.48
- Technical
- Relative Strength Index (RSI)
- BRNS 48.42
- BCTX 32.77
- Support Level
- BRNS $0.91
- BCTX $0.38
- Resistance Level
- BRNS $1.15
- BCTX $0.42
- Average True Range (ATR)
- BRNS 0.15
- BCTX 0.05
- MACD
- BRNS -0.01
- BCTX -0.01
- Stochastic Oscillator
- BRNS 34.96
- BCTX 4.12
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.